Creating access to expert knowledge from China

China Access Bootcamp was successful – virtual delegation trip to follow

The "China Access Bootcamp", organized by the MAGIA2Market project partners and Life Science Nord, took place from March 1 to 3. The three-day online event enabled participants to get an in-depth understanding of the Chinese MedTech market and contributes to their ability to strategically prepare their market entry. The focus of the presentations and discussions was on topics such as the regulation of medical devices as well as financing options and intellectual property rights. The bootcamp was part of the preparation for a virtual delegation trip to China, an activity within the framework of the EU-funded project MAGIA2Market at the end of March 2022.

3 modules for know-how transfer

Together with the two Chinese partners, the Research Institute of Tsinghua University in Shenzhen (RITS) and Leaguer Bio-Tech, participants from interested life science companies had the opportunity to take part in the three modules

  • Shenzhen's Business Environment and Internationalization – Overview of medical device regulations in China
  • Basic legal knowledge and provisions of international cooperation
  • IP Protection – Investment & Financing

to benefit from the knowledge of regional experts and to gain a broad but also detailed insight into the Chinese market. For those who participated, joining the online bootcamp was well worth it. "The Chinese market is a large market for us and having this great opportunity to learn more about the market and its regulations is a good preparation as we start to address its potential," emphasized participant Simon Myrbäck, Business Development Manager, Cellbox Solutions GmbH. In addition to Cellbox Solutions, Life Science Nord members Anacyte Laboratories GmbH and m-u-t GmbH also used the opportunity to take part in the market know-how of the bootcamp's speakers and as preparation for their upcoming participation in the virtual journey.

Sarah Niemann, Manager International Affairs at Life Science Nord, supports companies from the LSN cluster in internationalization projects as part of MAGIA2Market.

"The Access Bootcamp was a successful kick-off for the virtual delegation trip to China that is coming up soon. The knowledge imparted enables the companies to better assess how they should proceed with a possible market entry. With the delegation trip, we want to give the companies traveling with us the opportunity to set foot in the Chinese life science market in a very concrete way," says Sarah Niemann, Manager International Affairs at Life Science Nord, who is actively promoting networking activities between Europe and China together with the MAGIA2Market project partners.

More News

GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)
GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)

Pacira BioSciences Acquires GQ Bio

HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...

Read more …
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)

CrystalsFirst Scales Operations...

CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...

Read more …
medac has received FDA approval for treosulfan (Copyright Adobe Stock - Nicolas Hermbach)

Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT

medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...

Read more …